Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

postmenopausal osteoporosis

- PMLiVE

UCB to sell Biogen Idec’s MS drugs in Asia

Includes Tysabri and Tecfidera

- PMLiVE

Amgen cholesterol antibody scores in another phase III trial

Evolocumab effective in patients who cannot take statins

- PMLiVE

Peacock steps down as Amgen CFO

Michael Kelly appointed acting financial head

- PMLiVE

Amgen throws its hat into the cholesterol antibody ring

Evolocumab set for a race to market with Sanofi/Regeneron and Pfizer

- PMLiVE

Matthew Speers appointed as new chief executive of PAGB

UCB's former UK and Ireland general manager will take up post next year

- PMLiVE

UCB files Vimpat for expanded epilepsy use

Submits monotherapy application to FDA


- PMLiVE

Amgen buys total filgrastim rights from Roche

Wrests control of white blood cell stimulator franchise

- PMLiVE

AZ/Amgen report positive data with psoriasis antibody

Brodalumab shows efficacy in achieving and maintaining clear skin

Novartis building

Novartis’ psoriasis drug set to challenge Amgen/Pfizer’s Enbrel

Secukinumab shows superior efficacy in phase III trial

- PMLiVE

UCB wins extra Cimzia approval in US

FDA backs drug for use in patients with active psoriatic arthritis 

- PMLiVE

VIDEO interview: Neil Weir, UCB

Senior vice president of global research at UCB discusses the importance of patient-centricity and the value of collaboration

- PMLiVE

Amgen drug misses endpoint in acute heart failure trial

Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links